Publication | Closed Access
Polymer Nanoparticles - A Novel Strategy for Administration of Paclitaxel in Cancer Chemotherapy
19
Citations
0
References
2012
Year
NanoparticlesTissue EngineeringEngineeringBiomedical EngineeringActive TargetingCancer ChemotherapyPolymer NanoparticlesNanomedicineHydrogelsTherapeutic NanomaterialsMatrix BiologyDrug Delivery SystemRadiation OncologyPolymer ChemistryNovel StrategyMedicineTumor TargetingPharmacologyPolymer-drug ConjugatePaclitaxel DeliveryPharmaceutical NanotechnologyDrug Delivery SystemsNano-drug DeliveryPoor SolubilityOncology
The main challenge encountered while treating using Paclitaxel (PTX) is its poor solubility in aqueous solutions. The cremophor used in the formulation can cause various side effects such as hypersensitivity, myelosuppression and neurotoxicity and also leads to non-specific distribution in tumor and normal tissues. Since the structure of Paclitaxel does not possess a functional group, it is not easy to manipulate to enhance the solubility. Such limitations can be overcome by delivering Paclitaxel with the aid of drug delivery systems such as polymeric micelles, nanoparticles, hydrogels and liposomes. The review discusses various approaches of Paclitaxel delivery via polymeric nanoparticles. It focuses on the passive and active targeting of Paclitaxel.